Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Exec compensation

<< Previous

Bullboard Posts

Next >>

Comment by jkljklon Dec 12, 2023 12:33pm

198 Views

Post# 35780179

RE:Exec compensation

The group who invested 17 million dollars a few months ago I'm wondering how they feel after this major kick in the teeth. Are they corresponding with Onc or are they like the rest of us taking this in stride and hoping the near future will be more promising

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it